NCT06422832

Brief Summary

Heart failure, characterized by high mortality and morbidity rates, frequent hospital admissions, and prolonged stays in cardiology wards, significantly impacts patients' quality of life. The REMOTI-HF is a single-center randomized controlled trial designed to assess the impact of remote monitoring, utilizing the HeartLogic and TriageHF algorithms, in patients with heart failure with implantable cardioverter defibrillator or cardiac resynchronization therapy. The primary endpoints include mortality, hospital admissions related to heart failure, and visits for worsening heart failure. Moreover, we will explore the full capabilities of these algorithms, by analysing the association of physical activity, measured by the devices, with the same key outcomes. Additionally, the research will explore the relationship between the absolute values provided by the algorithms and NT-proBNP values.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
270

participants targeted

Target at P75+ for not_applicable heart-failure

Timeline
1mo left

Started Jul 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jul 2024Jul 2026

First Submitted

Initial submission to the registry

May 15, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 21, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

May 21, 2024

Status Verified

May 1, 2024

Enrollment Period

7 months

First QC Date

May 15, 2024

Last Update Submit

May 15, 2024

Conditions

Keywords

Heart FailureRemote MonitoringICDCRT

Outcome Measures

Primary Outcomes (1)

  • Primary Composite Outcome

    All-cause mortality, Hospital Admission for Heart Failure, Ventricular Arrhythmias and Worsening Heart Failure as defined in the secondary outcome area.

    2 years

Secondary Outcomes (5)

  • All-cause mortality

    2 years

  • Hospital admission for Heart Failure

    2 years

  • Worsening Heart failure

    2 eras

  • Ventricular Arrhythmias

    2 years

  • Atrial Arrhytmias

    2 years

Study Arms (2)

Interventional group

EXPERIMENTAL

In this group the respective algorithm will be activated and alerts will be sent according to its design

Other: HeartLogic or TriageHF Algorithms for implantable devices

Control Group

NO INTERVENTION

The algorithm will not be activated and follow-up will continue as if the patient was not included in the study.

Interventions

Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design

Interventional group

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Possession of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device that is compatible with the HeartLogic or TriageHF algorithms.
  • Left ventricular ejection fraction at the time of device implantation must be equal to or less than 35%.

You may not qualify if:

  • Younger than 18 years old or older than 85 years old.
  • Unable to be contacted when out of the hospital.
  • Presence of severe cognitive impairment.
  • Currently on the heart transplant waiting list

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Heart FailureArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Gonçalo Batista, MD

    ULS Coimbra

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gonçalo Batista, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Patients will not know whether the algorithms was activated or not at the beginning of the study. However, if a contact with the patient is made due to the algorithm, the patient will then understand they are not on the control group. The person responsible for contacts will also know if an individual patient is on the control or intervention group.
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Cardiology Resident

Study Record Dates

First Submitted

May 15, 2024

First Posted

May 21, 2024

Study Start

July 1, 2024

Primary Completion

February 1, 2025

Study Completion (Estimated)

July 1, 2026

Last Updated

May 21, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share